| | | | | | | | | | |
|
|
| Dockets Entered
On March 3, 2005
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1980N-0208
|
| Biological Products; Bacterial Vaccines and Toxiods
|
|
|
| 1983G-0318
|
| GUM ACACIA IN ALCOHOLIC BEVERAGES
|
|
|
| 1992V-0225
|
| Laser Light Show
|
|
|
| 1993N-0348
|
| Lead in Food & Color Additives & GRAS Ingredients
|
|
|
| 1994P-0036
|
| Req labeling of trans fatty acid & prohibit deceptive claims
|
|
|
| 2002N-0277
|
| Bioterrorism; Establishment & Maintenance of Records
|
|
|
| 2002V-0382
|
| Infrared Laser Aiming Devices
|
|
|
| 2003D-0386
|
| Guidance for Industry on Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP
|
|
|
| 2003F-0023
|
| Creamers for Use in Alcoholic Beverages
|
|
|
| 2003N-0528
|
| Revision of the Requirements for Spore-Forming Microorganisms
|
|
|
| 2004D-0369
|
| Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by Bioengineered Plants Intended for Food Use
|
|
|
| 2004D-0478
|
| Guidance for Industry and Food and Drug Administration; Class II Special Controls Guidance Document: Implantable Radiofrequency Transponder System for Patient Identification and Health Information
|
|
|
|
|
|
| 2004D-0494
|
| Guidance for Industry on Changes to an Approved NDA or ANDA; Specifications Use of Enforcement Discretion for Compendial Changes
|
|
|
| 2004D-0524
|
| Draft Guidance for Industry on ANDAs: Pharmaceutical Solid Polymorphism; Chemistry, Manufacturing, and Controls Information
|
|
|
| 2004N-0269
|
| Radioactive Drug Research Committees; Agency Information Collection Activities
|
|
|
| 2004N-0355
|
| Scientific Considerations Related to Developing Follow-on Protein Products
|
|
|
| 2004N-0395
|
| Agency Information Collection Activities: Proposed Collection; Comment Request; Application for Participation in the Medical Device Fellowship Program
|
|
|
| 2004P-0464
|
| Vitamin D and Calcium and Reduced Risk of Osteoporosis
|
|
|
| 2004Q-0201
|
| Qualified Health Claim (QHC): Lycopene, Tomatoes and Various Cancers
|
|
|
| 2005D-0056
|
| Guidance for Industry: Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular a
|
|
|
|
|
|
| 2005N-0038
|
| Reporting of Adverse Events to Institutional Review Boards; Public Hearing
|
|
|
| 1980N-0208
|
| Biological Products; Bacterial Vaccines and Toxiods
|
|
|
| C 8
|
| C. Thayer
|
| Vol #:
|
| 142
|
|
|
| C 9
|
| B. Franz
|
| Vol #:
|
| 142
|
|
|
| C 10
|
| P. Veldhuis
|
| Vol #:
|
| 142
|
|
|
| EC 30
|
| Mr. Brian Cox
|
| Vol #:
|
| 140
|
|
|
| 1983G-0318
|
| GUM ACACIA IN ALCOHOLIC BEVERAGES
|
|
|
| NWL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 1992V-0225
|
| Laser Light Show
|
|
|
| VRA
3
|
| HFZ-300 to Forum Developers Limited Partnership
|
| Vol #:
|
| 1
|
|
|
| 1993N-0348
|
| Lead in Food & Color Additives & GRAS Ingredients
|
|
|
| NWL
1
|
| FDA
|
| Vol #:
|
| 3
|
|
| | | | | | | | |
|
|
| 1994P-0036
|
| Req labeling of trans fatty acid & prohibit deceptive claims
|
|
|
| C 2652
|
| H. Hansen
|
| Vol #:
|
| 90
|
|
|
| 2002N-0277
|
| Bioterrorism; Establishment & Maintenance of Records
|
|
|
| NAL
1
|
| FDA
|
| Vol #:
|
| 16
|
|
|
| NCR
2
|
| FDA
|
| Vol #:
|
| 16
|
|
|
| SS
1
|
| Supporting Statement
|
| Vol #:
|
| 16
|
|
|
| 2002V-0382
|
| Infrared Laser Aiming Devices
|
|
|
| AMD
1
|
| Laser Devices, Inc.
|
| Vol #:
|
| 1
|
|
|
| 2003D-0386
|
| Guidance for Industry on Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP
|
|
|
| NWL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2003F-0023
|
| Creamers for Use in Alcoholic Beverages
|
|
|
| BKG
1
|
| Background Material Refs 1 - 9 70FR8032
|
| Vol #:
|
| 2
|
|
|
| NFR
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2003N-0528
|
| Revision of the Requirements for Spore-Forming Microorganisms
|
|
|
| GDL
1
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
| NAD
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2004D-0369
|
| Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by Bioengineered Plants Intended for Food Use
|
|
|
| EMC 1071
|
| P Zarchin
|
| Vol #:
|
| 14
|
|
|
| EMC 1072
|
| T Dolan
|
| Vol #:
|
| 14
|
|
|
| EMC 1073
|
| B Cutler
|
| Vol #:
|
| 14
|
|
|
| EMC 1074
|
| J Siegel
|
| Vol #:
|
| 14
|
|
|
| EMC
1075
|
| Friends of the Earth
|
| Vol #:
|
| 14
|
|
|
| EMC 1076
|
| B Stockton
|
| Vol #:
|
| 14
|
|
|
| EMC 1077
|
| B Smawley
|
| Vol #:
|
| 14
|
|
|
| EMC 1078
|
| M Hill
|
| Vol #:
|
| 14
|
|
|
| EMC 1079
|
| F Stiff
|
| Vol #:
|
| 14
|
|
|
| EMC 1080
|
| S Abbott
|
| Vol #:
|
| 14
|
|
|
| EMC 1081
|
| L McAllister
|
| Vol #:
|
| 14
|
|
|
| EMC 1082
|
| J Gonzales
|
| Vol #:
|
| 14
|
|
|
| EMC 1083
|
| M Bird
|
| Vol #:
|
| 14
|
|
|
| EMC 1084
|
| B Winholtz
|
| Vol #:
|
| 14
|
|
|
| EMC 1085
|
| L Hutchins
|
| Vol #:
|
| 14
|
|
|
| EMC 1086
|
| M White
|
| Vol #:
|
| 14
|
|
| | | | | | | | |
|
|
| EMC 1198
|
| E Heisler
|
| Vol #:
|
| 18
|
|
|
| EMC 1199
|
| J Mueller
|
| Vol #:
|
| 18
|
|
|
| 2004D-0478
|
| Guidance for Industry and Food and Drug Administration; Class II Special Controls Guidance Document: Implantable Radiofrequency Transponder System for Patient Identification and Health Information
|
|
|
|
|
|
|
| EC
2
|
| SEGURITECH PRIVADA S.A. DE C.V.
|
| Vol #:
|
| 1
|
|
|
| 2004D-0494
|
| Guidance for Industry on Changes to an Approved NDA or ANDA; Specifications Use of Enforcement Discretion for Compendial Changes
|
|
|
| EC
1
|
| Eli Lilly and Company
|
| Vol #:
|
| 1
|
|
|
| 2004D-0524
|
| Draft Guidance for Industry on ANDAs: Pharmaceutical Solid Polymorphism; Chemistry, Manufacturing, and Controls Information
|
|
|
| EC
1 , attachment |
| Eon Labs, Inc.
|
| Vol #:
|
| 1
|
|
|
| 2004N-0269
|
| Radioactive Drug Research Committees; Agency Information Collection Activities
|
|
|
| NAL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| SS
1
|
| Supporting Statement
|
| Vol #:
|
| 1
|
|
|
| 2004N-0355
|
| Scientific Considerations Related to Developing Follow-on Protein Products
|
|
|
| NEC
1
|
| FDA
|
| Vol #:
|
| 4
|
|
|
| 2004N-0395
|
| Agency Information Collection Activities: Proposed Collection; Comment Request; Application for Participation in the Medical Device Fellowship Program
|
|
|
| NAL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| SS
1
|
| Supporting Statement
|
| Vol #:
|
| 1
|
|
|
| 2004P-0464
|
| Vitamin D and Calcium and Reduced Risk of Osteoporosis
|
|
|
| LET
2
|
| Beverage Institute for Health and Wellness (BHWI)
|
| Vol #:
|
| 9
|
|
|
| 2004Q-0201
|
| Qualified Health Claim (QHC): Lycopene, Tomatoes and Various Cancers
|
|
|
| RC
1
|
| American Longevity Inc
|
| Vol #:
|
| 16
|
|
|
| 2005D-0056
|
| Guidance for Industry: Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular a
|
|
|
|
|
|
|
| BKG
1
|
| Background Material Refs 1 - 5 70FR9083
|
| Vol #:
|
| 1
|
|
|
| GDL
1
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
| NAD
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2005N-0038
|
| Reporting of Adverse Events to Institutional Review Boards; Public Hearing
|
|
|
| APE 6
|
| CIOMS VI Working Group
|
| Vol #:
|
| 1
|
|
|
| EAPE 154
|
| Foss, Jim
|
| Vol #:
|
| 1
|
|
|
| EAPE 155
|
| Waterman, Paula Squire
|
| Vol #:
|
| 1
|
|
|
| EAPE 156
|
| Lasswell, M'Linda
|
| Vol #:
|
| 1
|
|